Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:AVIRNASDAQ:NATRNASDAQ:OSMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$13.33-0.6%$11.14$7.08▼$16.37$276.02M0.7175,132 shs44,359 shsAVIRAtea Pharmaceuticals$3.21$2.95$2.46▼$4.15$274.71M0.18317,265 shs369,295 shsNATRNature's Sunshine Products$14.65-1.5%$13.58$10.81▼$18.06$270.49M1.1646,896 shs54,224 shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%-0.37%+19.98%+45.81%-8.71%AVIRAtea Pharmaceuticals0.00%0.00%+10.69%-0.31%-8.02%NATRNature's Sunshine Products0.00%+1.38%-0.07%+18.24%-2.46%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.4417 of 5 stars0.54.00.00.02.00.00.6AVIRAtea Pharmaceuticals2.6706 of 5 stars3.34.00.00.00.02.51.3NATRNature's Sunshine Products2.0999 of 5 stars3.54.00.00.00.61.70.0OSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.00Sell$7.00-47.49% DownsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0086.92% UpsideNATRNature's Sunshine Products 3.00Buy$18.3325.14% UpsideOSMTOsmotica Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OSMT, AMRN, NATR, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025NATRNature's Sunshine ProductsDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.005/7/2025NATRNature's Sunshine ProductsDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/14/2025NATRNature's Sunshine ProductsDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.21N/AN/A$23.62 per share0.56AVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ANATRNature's Sunshine Products$454.36M0.60$1.25 per share11.73$8.71 per share1.68OSMTOsmotica Pharmaceuticals$177.88M0.00N/A1.00$1.50 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)AVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)NATRNature's Sunshine Products$7.70M$0.5327.64∞N/A2.22%6.98%4.63%8/6/2025 (Estimated)OSMTOsmotica Pharmaceuticals-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/ALatest OSMT, AMRN, NATR, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A5/6/2025Q1 2025NATRNature's Sunshine Products$0.16$0.25+$0.09$0.25$109.39 million$113.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/AOSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.532.55AVIRAtea PharmaceuticalsN/A19.9419.94NATRNature's Sunshine ProductsN/A2.411.50OSMTOsmotica PharmaceuticalsN/A0.430.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%AVIRAtea Pharmaceuticals86.67%NATRNature's Sunshine Products79.40%OSMTOsmotica Pharmaceuticals46.18%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%AVIRAtea Pharmaceuticals18.10%NATRNature's Sunshine Products4.70%OSMTOsmotica Pharmaceuticals5.22%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million20.02 millionOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableNATRNature's Sunshine Products85018.46 million17.60 millionOptionableOSMTOsmotica Pharmaceuticals30262.59 million59.32 millionNot OptionableOSMT, AMRN, NATR, and AVIR HeadlinesRecent News About These CompaniesDuane Jose Saltmer and Ravindra Deo Narayan of OSMG and OSMT sentenced to jail for $4 million tax evasion schemeSeptember 6, 2024 | townsvillebulletin.com.auVanda Pharmaceuticals Inc.March 6, 2024 | wsj.comRVL Pharmaceuticals PLC (RVLPQ)December 19, 2023 | investing.comOther OTC Pharmaceuticals - SeychellesOctober 8, 2023 | statista.comOsmotica Pharmaceuticals is about to announce its earnings — here's what to expectAugust 14, 2023 | markets.businessinsider.comWhat Wall Street expects from Osmotica Pharmaceuticals's earningsMarch 19, 2023 | markets.businessinsider.comGRO Biosciences Appoints Rakhshita Dhar to its Board of DirectorsJanuary 19, 2022 | nz.finance.yahoo.comUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 19, 2022 | finance.yahoo.comOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'January 19, 2022 | benzinga.comOsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceJanuary 19, 2022 | finance.yahoo.comRVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022January 18, 2022 | finance.yahoo.comFresh Insights On Osmotica Pharmaceuticals plc (OSMT)January 15, 2022 | stocksregister.comOsmotica Pharmaceuticals plc (OSMT): What Is Good About Stock?January 11, 2022 | marketingsentinel.comOsmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022January 6, 2022 | finance.yahoo.comBoom Or Bust: What Are Osmotica Pharmaceuticals plc’s (NASDAQ:OSMT) Future Prospects?January 1, 2022 | marketingsentinel.comOsmotica Pharmaceuticals plc (NASDAQ: OSMT) Shares Rose Recently. However, Trouble May Still Be Lurking.December 27, 2021 | stocksregister.comOsmotica Pharmaceuticals plc (NASDAQ: OSMT): Why Investors Shouldn’t Ditch OSMT Stock In 2021December 27, 2021 | marketingsentinel.comOsmotica Pharmaceuticals plc (NASDAQ:OSMT) Shares Plunged 0.00% In A Week – But Will They Keep Going Up?December 23, 2021 | marketingsentinel.comJames Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More SharesDecember 22, 2021 | nasdaq.comOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceDecember 20, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSMT, AMRN, NATR, and AVIR Company DescriptionsAmarin NASDAQ:AMRN$13.33 -0.08 (-0.60%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$13.23 -0.10 (-0.75%) As of 06/18/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Atea Pharmaceuticals NASDAQ:AVIR$3.21 0.00 (0.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.21 0.00 (0.00%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Nature's Sunshine Products NASDAQ:NATR$14.65 -0.23 (-1.55%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$14.64 -0.02 (-0.10%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Osmotica Pharmaceuticals NASDAQ:OSMTOsmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
